CanBas Co., Ltd.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

14

Website

www.canbas.co.jp

Country

Japan

Exchange

Tokyo

CanBas Co., Ltd., a clinical stage biopharmaceutical company provides the basic research and clinical development of anti-cancer drugs. It develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.

Key Stats

52-Week Range

¥506.00¥1558.00

Beta-0.84

Trailing P/EN/A

Forward P/EN/A

Trailing EPS-64.24

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.